CD8A and neoplasm: Elevated PD-L1 levels subsequently inhibit the anti-tumor activity of CD8+ T cells, promote OSCC cell proliferation, migration, invasion, and the EMT process, ultimately facilitating immune escape and accelerating tumor progression.